Randomized Conversion of EBV+ Kidney Transplant Recipients of Living or Standard Criteria Donors at Three Months Post Transplantation to Belatacept with MPA or Belatacept with Low-Dose Tacrolimus (50% of Dose) Compared to Patients Remaining on Center Spec

Project: Research project

Project Details

StatusActive
Effective start/end date9/9/149/9/22

Funding

  • Bristol-Myers Squibb Company (Agmt 09/09/14)